Drug Profile
Devimistat - Cornerstone Pharmaceuticals Inc
Alternative Names: 6,8-bis(benzylthio)octanoic-acid; Bylantra; CPI-613; ONO-7912Latest Information Update: 07 Sep 2023
Price :
$50
*
At a glance
- Originator Cornerstone Pharmaceuticals; Stony Brook University
- Developer Case Comprehensive Cancer Center; Cornerstone Pharmaceuticals Inc; National Cancer Institute (USA); Ono Pharmaceutical; University of Michigan; Wake Forest University Health Sciences; Wake Forest University School of Medicine
- Class Antineoplastics; Carboxylic acids; Coenzymes; Fatty acids; Small molecules; Sulfides
- Mechanism of Action Ketoglutarate dehydrogenase complex inhibitors; Pyruvate dehydrogenase complex inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Acute myeloid leukaemia; Pancreatic cancer
- Phase II B-cell lymphoma; Burkitt's lymphoma; Small cell lung cancer; Solid tumours; T-cell lymphoma
- Phase I/II Biliary cancer; Cancer; Clear cell sarcoma; Colorectal cancer
- Phase I Hodgkin's disease
- Discontinued Myelodysplastic syndromes
Most Recent Events
- 28 Aug 2023 Cornerstone Pharmaceuticals withdraws the phase I trial for Colorectal cancer (Combination therapy, Metastatic- disease, Second-line therapy or greater) (IV, Infusion), prior to enrolment due to no funding (NCT05070104)
- 16 May 2023 Cornerstone Pharmaceuticals plans a phase II trial for Acute myeloid leukemia (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV, Infusion) (NCT05854966)
- 14 Apr 2023 Pharmacodynamics data from a preclinical study in Cholangiocarcinoma presented at the 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)